BIBW 1200.23
Laufzeit: 01.01.2009 - 31.12.2010
Kurzfassung
Randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non-small cell lung cancer patients failing Erlotinib or Gefitinib (LUX-Lung 1)
Laufzeit: 01.01.2009 - 31.12.2010
Randomized, double-blind trial of BIBW 2992 plus best supportive care (BSC) versus placebo plus BSC in non-small cell lung cancer patients failing Erlotinib or Gefitinib (LUX-Lung 1)
